Outcome of special types of luminal breast cancer

Marco Colleoni(European Institute of Oncology), Giulia Viale(Istituti di Ricovero e Cura a Carattere Scientifico), Patrick Maisonneuve(European Institute of Oncology), Alberto Luini(Institute for Experimental Endocrinology and Oncology), A. Cardillo, Gino Perri, Emilia Montagna, Mauro G. Mastropasqua(University of Milan), Giuseppe Cancello, Giancarlo Pruneri(University of Milan), Nicole Rotmensz(European Organisation for Research and Treatment of Cancer), Mattia Intra, Paolo Veronesi(Ripamonti), Monica Iorfida, Aron Goldhirsch(Istituti di Ricovero e Cura a Carattere Scientifico), Massimiliano Mazza(University of Milan)
Annals of Oncology
October 30, 2011
10.1093/annonc/mdr461
Cited by 123

Related Papers

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
|Annals of Oncology|2013|3.7k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k